<DOC>
	<DOCNO>NCT01339468</DOCNO>
	<brief_summary>The purpose study investigate compare pharmacokinetic parameter tacrolimus Advagraf Prograf de nove live donor liver transplant recipient .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics , Safety Efficacy Advagraf Prograf de Novo Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>subject receive primary , partial liver graft live donor subject must receive first dose tacrolimus corticosteroid operation expect maintain tacrolimus throughout study . MMF could combine subject receive multiorgan transplant previously receive organ transplant ( include liver retransplantation ) subject receive auxiliary graft bioartificial liver ( cell system ) use subject allergic intolerant macrolide antibiotic tacrolimus subject require immunosuppressive treatment / systemic chemotherapy prior transplantation subject malignancies history malignancy within last 5 year , exception basalioma squamous cell carcinoma skin subject systemic infection require treatment , except viral hepatitis subject severe diarrhoea , vomit , active peptic ulcer gastrointestinal disorder may affect absorption tacrolimus subject serum creatinine &gt; 1.5mg/dl subject take take potassium preserve diuretic subject form substance abuse , psychiatric disorder condition , opinion investigator , may complicate communication investigator subject participate participate another clinical trial and/or take take investigational / nonregistered drug past 28 day subject donor know HIV positive donor know HBV , HCV positive and/or IgM positive CMV , EBV</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>live donor liver transplantation</keyword>
	<keyword>FK506</keyword>
	<keyword>prograf</keyword>
	<keyword>advagraf</keyword>
	<keyword>Immunosuppressant</keyword>
</DOC>